Recce Pharmaceuticals Ltd. announced, in accordance with ASX Listing Rule 3.16.1, the appointment of Alistair McKeough as Non-Executive Director and Maggie Niewidok as Company Secretary, effective 1 September 2022. Alistair is a solicitor with extensive operational and board experience in many sectors, including professional services, technology, biotechnology, financial services, education and charities. He was formerly Head of Professional Services at Automic Group, which acquired his legal, company secretarial and corporate governance business, Whittens & McKeough, in 2018.

Alistair was Managing Director of the firm at that time. He is currently the Chair of the Waratah Education Foundation. Alistair has had deep leadership experience in many high performing companies, in which he has had responsibility for a range of organisational performance outcomes including safety and risk management, corporate governance, legal compliance, cost reduction, strategy, change management, M&A, capital raising, culture and value creation.

Alistair has immediately stepped out of the company secretary role to become a director of Recce, having served as Recce Pharmaceuticals' Company Secretary and primary legal adviser from 29 November 2017 to 31 August 2022. The Board now welcomes Alistair's governance and legal expertise in the role of non-executive director. Alistair will also assume the role of Chair of the Company's Audit & Risk Management Committee.

Maggie Niewidok takes on the role of Company Secretary. Maggie is an experienced solicitor and company secretary who has worked across a broad industry base of ASX listed companies. For the purposes of ASX Listing Rule 12.6, Ms Niewidok will be the person responsible for communications between the Company and ASX.